Phase 1 Study of DS-6051b in Japanese Subjects With Advanced Solid Malignant Tumors

Inclusion Criteria: * Advanced solid malignant tumors that are refractory to standard therapy or for which no standard therapy is available. * An Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1. Exclusion Criteria: * Previously had or currently has any of the following diseases: Cardiac failure (NYHA Functional Classification ≥ Class III), myocardial infarction, cerebral infarction, unstable angina, arrhythmia requiring treatment, coronary/peripheral artery disease, pulmonary thrombosis, uncontrolled deep vein thrombosis, clinically severe thromboembolic event, or autoimmune disease requiring treatment. * Previously had or currently has clinically severe pulmonary disease (eg, interstitial pneumonia, pneumonitis, pulmonary fibrosis, radiation pneumonia). * Severe or uncontrolled concomitant disease. * Clinically active brain metastases or central nervous system tumor requiring steroid or anticonvulsant treatment.